Drug Profile
Naporafenib - Novartis
Alternative Names: ERAS-254; LXH-254Latest Information Update: 15 Dec 2023
Price :
$50
*
At a glance
- Originator Novartis
- Developer Erasca; Novartis
- Class Amides; Antineoplastics; Fluorocarbons; Morpholines; Pyridines; Small molecules
- Mechanism of Action Raf kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Malignant melanoma
- Phase I Colorectal cancer; Non-small cell lung cancer; Solid tumours
Most Recent Events
- 11 Dec 2023 Naporafenib receives Fast Track designation for Malignant melanoma [PO,Tablet] (Combination therapy, In adolescents, In children, In the elderly, Inoperable/Unresectable, Metastatic disease, Second-line therapy or greater, In adults) in USA
- 28 Nov 2023 Erasca plans the pivotal phase III SEACRAFT-2 trial for Malignant melanoma (Metastatic disease, Combination therapy) (PO) , in H1 2024
- 17 Aug 2023 Phase-I clinical trials in Solid tumours (Combination therapy, In adolescents, In the elderly, Inoperable/Unresectable, Late-stage disease, Metastatic disease, In adults) in Canada, Australia, United Kingdom, South Korea (PO) (NCT05907304)